Reshma Kewalramani

Reshma Kewalramani
Birthplace	Bombay, India
Nationality	American
Occupation	CEO and President of Vertex Pharmaceuticals
Title	President and Chief Executive Officer
Employer	Vertex Pharmaceuticals
Known for	First female CEO of a large publicly traded U.S. biotechnology company
Education	Boston University (B.A./M.D., 1998); Harvard Business School General Management Program (2015)

'Reshma Kewalramani is an American physician and biotechnology executive who serves as the president and chief executive officer of Vertex Pharmaceuticals, a Boston-based biotechnology company known for its transformative treatments for cystic fibrosis and other serious diseases. She assumed the role on April 1, 2020, becoming the first woman to lead a large, publicly traded biotechnology company in the United States. Born in Bombay, India, Kewalramani immigrated to the United States as a child and went on to train as a nephrologist before pivoting to careers in the pharmaceutical industry and biotech leadership. Under her leadership, Vertex has expanded beyond its cystic fibrosis franchise into new therapeutic areas including pain, kidney disease, and gene editing, while achieving significant revenue growth and a market capitalization exceeding $80 billion. In 2025, she was named to Time magazine's list of the 100 Most Influential People and Fortunes list of the 100 Most Powerful People in Business.

Early Life

Reshma Kewalramani was born in Bombay (now Mumbai), India. She immigrated to the United States at the age of 11. According to profiles published at the time of her appointment as CEO, Kewalramani was raised by parents who encouraged her interest in science and medicine, and who had long hoped she would become a doctor. Kewalramani has stated that she felt destined to pursue a career in science and medicine from an early age.

Her experience as an immigrant to the United States shaped her outlook and career trajectory. A profile in Time magazine noted that her journey from India to the leadership of one of America's largest biotechnology companies reflected a broader narrative of immigrant achievement in the American biotech and technology industries. In 2025, NDTV reported on Kewalramani's inclusion alongside other Indian-origin business leaders such as Satya Nadella and Sundar Pichai in Fortune's ranking of the most powerful people in business, underscoring her prominence among Indian-origin executives leading major global corporations.

Education

Kewalramani attended Boston University, where she completed a combined Bachelor of Arts and Doctor of Medicine (B.A./M.D.) program, earning her degrees in 1998. The accelerated dual-degree program at Boston University allowed her to complete both her undergraduate and medical education in a condensed timeframe.

After completing her medical degree, Kewalramani trained as a nephrologist — a physician specializing in kidney diseases. She was a member of the Kidney Health Initiative (KHI) Board of Directors of the American Society of Nephrology, reflecting her specialization and involvement in the nephrology community.

In 2015, Kewalramani completed the General Management Program at Harvard Business School, adding formal business training to her medical credentials. This combination of clinical expertise and business education became a distinguishing feature of her leadership profile in the biotechnology industry.

Career

Early Medical and Pharmaceutical Career

After her training in nephrology, Kewalramani transitioned from clinical medicine into the pharmaceutical and biotechnology sectors. Her clinical background in kidney disease later informed aspects of Vertex's strategic expansion into treatments for kidney-related conditions. The American Society of Nephrology's Kidney News noted her background in nephrology when she was named incoming president and CEO of Vertex Pharmaceuticals.

Vertex Pharmaceuticals: Chief Medical Officer

Before becoming CEO, Kewalramani served as Vertex Pharmaceuticals' executive vice president and chief medical officer (CMO), as well as vice president of global medicines development and medical affairs. In this capacity, she oversaw the company's clinical development programs and its global medical affairs operations. Her tenure as CMO coincided with a period of substantial growth for Vertex, driven by the success of its cystic fibrosis drug franchise, which included multiple approved therapies that became the standard of care for cystic fibrosis patients worldwide.

Appointment as President and CEO

On July 25, 2019, Vertex Pharmaceuticals announced that Kewalramani had been named as the company's next president and CEO, succeeding Jeffrey Leiden. The announcement attracted attention both in the business press and the broader media because Kewalramani became the first woman to serve as CEO of a large, publicly traded U.S. biotechnology company. The Boston Globe described the appointment as a milestone for the biotech industry, which had long been led predominantly by men at the executive level. MarketWatch and other financial outlets reported on the leadership transition as a significant event for one of the industry's most valuable companies.

Boston University highlighted Kewalramani as an alumna who had risen to the top of the biotech industry, noting her dual degree from the university and her rapid ascent through the pharmaceutical world.

Kewalramani officially assumed the CEO role on April 1, 2020, at the onset of the COVID-19 pandemic. The Boston Business Journal reported that she took the helm as the company was entering a new era in both leadership and drug development, with plans to expand well beyond its cystic fibrosis franchise.

Leadership and Strategic Expansion

Under Kewalramani's leadership, Vertex Pharmaceuticals pursued a diversification strategy aimed at extending the company's pipeline and product portfolio into new disease areas beyond cystic fibrosis. Key areas of expansion included gene editing therapies, treatments for pain, and therapies targeting kidney disease.

One of the most notable programs advanced during Kewalramani's tenure was the development of a CRISPR gene-editing treatment for sickle cell disease and beta-thalassemia, developed in collaboration with CRISPR Therapeutics. In 2021, STAT News reported on early results from a small study suggesting that the CRISPR-based treatment showed curative promise for patients with blood diseases. The therapy, known as Casgevy (exagamglogene autotemcel), later became one of the first CRISPR-based treatments to receive regulatory approval, marking a landmark in the field of gene therapy.

Vertex also pursued clinical development in kidney disease under Kewalramani's direction, including a pivotal trial targeting APOL1-mediated kidney disease, an area with significant unmet medical need that aligned with Kewalramani's own background as a nephrologist.

In pain therapeutics, Vertex developed suzetrigine (VX-548), a non-opioid pain treatment targeting a novel mechanism. This represented a potential breakthrough in the treatment of acute pain, a therapeutic area where new non-addictive alternatives to opioids were in demand.

The company's financial performance under Kewalramani's leadership reflected these strategic efforts. In 2024, Vertex reported a 12% jump in revenue, driven by continued expansion in its core cystic fibrosis business and early contributions from newer programs. The company's fourth-quarter 2024 results outpaced Wall Street's revenue expectations.

As of 2025, Vertex Pharmaceuticals maintained a market capitalization exceeding $80 billion, placing it among the largest biotechnology companies in the world. The company continued to participate actively in industry investor conferences, including the TD Cowen 46th Annual Health Care Conference in March 2026.

Compensation

In 2024, Kewalramani's total compensation was reported at $21.5 million, representing a 4% increase from the prior year, as disclosed in Vertex's proxy filings and reported by Fierce Pharma.

Board Memberships

Beyond her role at Vertex, Kewalramani has served on various boards and advisory bodies. She joined the board of directors of Ginkgo Bioworks, a synthetic biology company, in August 2021. She has also served as a trustee of Massachusetts General Hospital.

Kewalramani has been a member of the Dean's Advisory Board at the Boston University School of Medicine. She also previously served on the Board of Scientific Counselors and Policy (BSCP).

Recognition

Kewalramani has received numerous recognitions and honors for her leadership in the biotechnology and pharmaceutical industries.

In 2025, Time magazine named Kewalramani to its annual list of the 100 Most Influential People, citing her role as the first female CEO of a large, public U.S. biotechnology company and the impact of her leadership at Vertex. The same year, she was named to Time's TIME100 Health list, recognizing influential figures in health and medicine.

In August 2025, Fortune magazine included Kewalramani on its list of the 100 Most Powerful People in Business, placing her alongside other Indian-origin technology and business leaders including Satya Nadella and Sundar Pichai. NDTV reported on her inclusion as a noteworthy achievement for Indian-origin executives on the global business stage.

In 2025, Medical Marketing and Media (MM&M) named Kewalramani one of its Healthcare Marketing Influencers, recognizing her influence on the pharmaceutical landscape through her leadership of Vertex.

Earlier in her tenure, Kewalramani was named to the Boston Business Journal's Power 50 list in 2019, recognizing her as one of the most influential people in the Greater Boston business community.

In 2020, she was included in Business Insider's list of 300 People Transforming Business in North America, in the healthcare category.

She was also recognized by Indiaspora as one of its business leaders in 2020, reflecting her standing among the Indian diaspora in the United States.

The TiE Boston chapter recognized Kewalramani at its 2019 gala, as reported by India-West.

Legacy

Kewalramani's appointment and tenure at Vertex Pharmaceuticals have been viewed as a significant development in the representation of women in the leadership of the biotechnology and pharmaceutical industries. As the first woman to serve as CEO of a large, publicly traded U.S. biotech company, her career trajectory has been cited in discussions about gender equity in the life sciences sector.

Her background as an immigrant from India who rose to the top of one of America's most valuable biotech companies has also been highlighted as an example of the contributions of the Indian diaspora to the U.S. technology and healthcare sectors. Profiles in Time and other outlets have framed her story as emblematic of immigrant achievement in American business and science.

Under her leadership, Vertex's advancement of CRISPR-based gene-editing therapy for sickle cell disease and beta-thalassemia represented a milestone in the history of genetic medicine. The approval of Casgevy marked one of the first instances of a CRISPR-based treatment reaching patients, contributing to the establishment of gene editing as a viable therapeutic modality.

The Boston University School of Medicine alumni magazine profiled Kewalramani in its Winter 2020 edition, highlighting her as a distinguished alumna of the institution.

As of 2026, Kewalramani continues to lead Vertex Pharmaceuticals as it pursues further expansion of its therapeutic portfolio and pipeline, with the company maintaining its position among the largest and most valuable biotechnology firms globally.